Taubert Jennifer L

Jennifer L. Taubert, Executive Vice President and Worldwide Chair of Pharmaceuticals at Johnson & Johnson (JNJ), has demonstrated a clear selling bias in her recent insider transactions, with $25.7 million in total sales outweighing $11.9 million in purchases across two companies. The bulk of her activity has centered on JNJ, where she executed a significant sell-off on September 4, 2025, unloading $10 million worth of shares outright and $5.75 million through market transactions. Her only other notable sales occurred earlier in 2024, including a $2.1 million transaction on February 12. By contrast, her buying activity has been limited to smaller, periodic acquisitions of McDonald's (MCD) stock—most recently $235,000 on December 31, 2025, following earlier $30,000 purchases in mid-2025. In 2026, Taubert's transactions have shifted entirely to derivative-based activity involving JNJ, with no open-market purchases. Her February 13, 2026, filing disclosed $3.3 million in derivative transactions, followed by smaller adjustments later that month. The absence of recent outright stock purchases, combined with her history of multimillion-dollar disposals, suggests a consistent pattern of reducing her JNJ equity exposure while maintaining minimal holdings in MCD. The data reflects a long-term trend of monetizing her executive compensation in JNJ rather than accumulating additional shares.